WuXi AppTec, Novogene Added To Pentagon List Of ‘Chinese Military Companies’
The Pentagon's list of Chinese companies owned and influenced by the military or government is expected to help shape BIOSECURE Act designations of "biotechnology companies of concern" due by December.
Scrip - June 10, 2026

AI And Robotics In Sperm Selection Bring More Predictability To IVF
Israeli start-up BAIBYS plans to take its innovative IVF technology to the US. CEO Yaron Silberman explained how the company’s technique uses a “Nespresso-like” workflow system incorporating AI and robotics to improve success rates and reduce birth defects.
Medtech Insight - June 10, 2026

FDA Clears BEMT As First New US Sunscreen Filter In Two Decades
The US FDA has approved BEMT as a new sunscreen active ingredient, giving US consumers access to a broader-spectrum UV filter long available in Europe and handing DSM-Firmenich 18 months of exclusive US marketing rights.
HBW Insight - June 10, 2026

Indian Court Overturns Injunction Against Intas’s Bevatas, Faults Sun
A Division Bench of the Delhi High Court has set aside a single Judge's order permanently restraining Intas from using the mark 'Bevatas' for its bevacizumab biosimilar and has rebuked complainant Sun Pharma for its conduct.
Generics Bulletin - June 9, 2026

Apotex Leads The Way On Januvia And Janumet Generics
Apotex is amongst the first to commercially launch its Januvia and Janumet generics, as it begins a shared 180-day shared exclusivity period launching both its sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, indicated for the treatment of type 2 diabetes mellitus.
Generics Bulletin - June 9, 2026

BsUFA IV: If Dates Known, US FDA Looks To Speed Biosimilar Approval Once Exclusivity Expires
The FDA proposed a goal date for biosimilars that are approvable and waiting for exclusivity to run out, but industry said expiration dates often are unknown.
Generics Bulletin - June 9, 2026

Reactions Roll In As Curtain Closes On The Hikma-Amarin Supreme Court Case
Hikma has secured victory in the long-running litigation with Amarin over skinny-label generic carve-outs. While the SCOTUS decision preserved the skinny-label regime, the grounds will be tested by future litigations.
Generics Bulletin - June 9, 2026

Alvotech Takes The Lead On Vedolizumab
Alvotech has secured FDA review of its proposed interchangeable intravenous Entyvio biosimilar AVT16, adding to EMA validation of a broader vedolizumab filing covering both IV and subcutaneous versions.
Generics Bulletin - June 9, 2026

Leaders At The Frontier: Conversations From SynBioBeta 2026
At SynBioBeta 2026, In Vivo spoke with founders, investors and platform builders at the intersection of synthetic biology and biopharma. Their conversations reveal a field maturing fast – but with clear-eyed leaders who know exactly where the hype ends and the hard work begins.
In Vivo - June 10, 2026